This week in therapeutics




Licensing status

Publication and contact information


Breast cancer

Retinoic acid receptor responder (tazarotene induced) 1
(RARRES1; TIG1); AXL receptor tyrosine kinase (AXL; UFO)

In vitro and mouse studies suggest inhibiting TIG1 could help treat inflammatory breast cancer. Inflammatory breast cancer is a rare form of the disease characterized by cancer cells that block the lymphatic vessels in the skin covering the breast. High TIG1 expression correlated with short overall survival in patients with the disease. In cultured inflammatory breast cancer cells, small hairpin RNA against TIG1 or an inhibitor of AXL, which is stabilized by TIG1, decreased cell proliferation, migration and invasion compared with shRNA or vehicle controls. In mice xenograft models of inflammatory breast cancer, shRNA against TIG1 decreased tumor growth compared with shRNA control. Next steps include developing a therapeutic that inhibits TIG1 or the interaction between TIG1 and AXL.
Rigel Pharmaceuticals Inc. and BerGenBio A/S have the AXL inhibitor BGB324 in Phase I testing to treat cancer.
Qurient Co. Ltd. has the AXL inhibitor Q-4 in preclinical testing to treat cancer.

SciBX 6(40); doi:10.1038/scibx.2013.1122
Published online Oct. 17, 2013

Findings unpatented; available for licensing

Wang, X. et al. Cancer Res.; published online Sept. 6, 2013;
Contact: Naoto T. Ueno, The University of Texas MD Anderson Cancer Center, Houston, Texas